-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The COVID-19 pandemic has brought huge economic and medical burdens to countries around the world.
COVID-19 stem cells
In April 2020, the study included 24 patients with severe COVID-19 and moderate to severe acute respiratory distress syndrome who were given ExoFlo treatment.
The results showed that all safety endpoints were reached, and no adverse events occurred within 72 hours after the administration of ExoFlo.
In general, after one treatment, the patient's clinical status and oxygen saturation were improved, and the average pressure of the arterial blood-oxygen ratio (PaO2/FiO2) increased by 192% (P <0.
In short, because of its security, resilience oxygenation, reduced cytokine storm and rebuild the immune force, making ExoFlo become the treatment of severe COVID-19 potential therapies.
immunity
Original source:
Vikram Sengupta, et al.
ncbi.
nlm.
nih.
gov/32380908/" target="_blank" rel="noopener">Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19 Leave a message here